Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
ACADIA PHARMACEUTICALS INC reported second quarter of 2023 results: revenue $140 to $144 million. Guidance reaffirmed.
- Period
- second quarter of 2023
- Revenue
- $140 to $144 million
- Guidance
- reaffirmed
- Result
- preliminary results
Exact text from the filing
DAYBUE 2Q 2023 preliminary net sales: $21 to $23 million.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
ACADIA PHARMACEUTICALS INC reported second quarter of 2023 results: revenue $140 to $144 million. Guidance reaffirmed.
- Period
- second quarter of 2023
- Revenue
- $140 to $144 million
- Guidance
- reaffirmed
- Result
- preliminary results
Exact text from the filing
NUPLAZID 2Q 2023 preliminary net sales: $140 to $144 million.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.99
ACADIA PHARMACEUTICALS INC entered into Joint Venture and License Agreement with Neuren Pharmaceuticals Limited valued at upfront payment $100.0 million; milestone payments up to $405.0 million per product; tiered double-d (effective 2023-07-13).
- Action
- entry
- Agreement
- license
- Counterparty
- Neuren Pharmaceuticals Limited
- Value
- upfront payment $100.0 million; milestone payments up to $405.0 million per product; tiered double-d
- Effective
- 2023-07-13
Exact text from the filing
On July 13, 2023, Acadia Pharmaceuticals Inc. (the “Company”) and Neuren Pharmaceuticals Limited (“Neuren”) entered into a joint venture and license agreement (the “License Agreement”) for the global commercialization and development of trofinetide and of Neuren’s development candidate NNZ-2591.
View on SEC.gov